Institution
Ochsner Medical Center
Healthcare•New Orleans, Louisiana, United States•
About: Ochsner Medical Center is a healthcare organization based out in New Orleans, Louisiana, United States. It is known for research contribution in the topics: Population & Medicine. The organization has 980 authors who have published 1159 publications receiving 49961 citations. The organization is also known as: Ochsner Hospital & Ochsner Foundation Hospital.
Papers published on a yearly basis
Papers
More filters
••
University of Pennsylvania1, Thomas Jefferson University2, Children's Hospital of Philadelphia3, Stanford University4, Emory University5, Boston Children's Hospital6, Alfred I. duPont Hospital for Children7, University of Mississippi8, Baylor College of Medicine9, Ochsner Medical Center10, University of Colorado Denver11, Arkansas Children's Hospital12, University of Michigan13, Children's Memorial Hospital14, St. Jude Children's Research Hospital15, University of Utah16, University of Texas Southwestern Medical Center17, Seattle Children's18
TL;DR: In this paper, the authors evaluate outpatient vs inpatient neutropenia management for pediatric acute myeloid leukemia (AML) in 17 US pediatric hospitals with frontline chemotherapy start dates ranging from January 2011 to July 2019, although the specific date ranges differed for individual analyses by design and relative timing.
Abstract: Importance Pediatric acute myeloid leukemia (AML) requires multiple courses of intensive chemotherapy that result in neutropenia, with significant risk for infectious complications. Supportive care guidelines recommend hospitalization until neutrophil recovery. However, there are little data to support inpatient over outpatient management. Objective To evaluate outpatient vs inpatient neutropenia management for pediatric AML. Design, setting, and participants This cohort study used qualitative and quantitative methods to compare medical outcomes, patient health-related quality of life (HRQOL), and patient and family perceptions between outpatient and inpatient neutropenia management. The study included patients from 17 US pediatric hospitals with frontline chemotherapy start dates ranging from January 2011 to July 2019, although the specific date ranges differed for the individual analyses by design and relative timing. Data were analyzed from August 2019 to February 2020. Exposures Discharge to outpatient vs inpatient neutropenia management. Main outcomes and measures The primary outcomes of interest were course-specific bacteremia incidence, times to next course, and patient HRQOL. Course-specific mortality was a secondary medical outcome. Results Primary quantitative analyses included 554 patients (272 [49.1%] girls and 282 [50.9%] boys; mean [SD] age, 8.2 [6.1] years). Bacteremia incidence was not significantly different during outpatient vs inpatient management (67 courses [23.8%] vs 265 courses [29.0%]; adjusted rate ratio, 0.73; 95% CI, 0.56 to 1.06; P = .08). Outpatient management was not associated with delays to the next course compared with inpatient management (mean [SD] 30.7 [12.2] days vs 32.8 [9.7] days; adjusted mean difference, -2.2; 95% CI, -4.1 to -0.2, P = .03). Mortality during intensification II was higher for patients who received outpatient management compared with those who received inpatient management (3 patients [5.4%] vs 1 patient [0.5%]; P = .03), but comparable with inpatient management at other courses (eg, 0 patients vs 5 patients [1.3%] during induction I; P = .59). Among 97 patients evaluated for HRQOL, outcomes did not differ between outpatient and inpatient management (mean [SD] Pediatric Quality of Life Inventory total score, 70.1 [18.9] vs 68.7 [19.4]; adjusted mean difference, -2.8; 95% CI, -11.2 to 5.6). A total of 86 respondents (20 [23.3%] in outpatient management, 66 [76.7%] in inpatient management) completed qualitative interviews. Independent of management strategy received, 74 respondents (86.0%) expressed satisfaction with their experience. Concerns for hospital-associated infections among caregivers (6 of 7 caregiver respondents [85.7%] who were dissatisfied with inpatient management) and family separation (2 of 2 patient respondents [100%] who were dissatisfied with inpatient management) drove dissatisfaction with inpatient management. Stress of caring for a neutropenic child at home (3 of 3 respondents [100%] who were dissatisfied with outpatient management) drove dissatisfaction with outpatient management. Conclusions and relevance This cohort study found that outpatient neutropenia management was not associated with higher bacteremia incidence, treatment delays, or worse HRQOL compared with inpatient neutropenia management among pediatric patients with AML. While outpatient management may be safe for many patients, course-specific mortality differences suggest that outpatient management in intensification II should be approached with caution. Patient and family experiences varied, suggesting that outpatient management may be preferred by some but may not be feasible for all families. Further studies to refine and standardize safe outpatient management practices are warranted.
4 citations
••
TL;DR: Clinical factors associated with pediatric peritonsillar abscess are reported, and it is found that, with the exception of leukocytosis, the signs/symptoms that prompted treatment correlate with those that indicate the presence of PTA.
Abstract: In this retrospective case series, we report clinical factors associated with pediatric peritonsillar abscess (PTA), with hopes of contributing to the design of an evidenced-based, economic treatment approach. Charts were examined for presenting symptoms and signs. Each of these were analyzed for association with the presence of PTA and for association with treatment. We found that, with the exception of leukocytosis, the signs/symptoms that prompted treatment correlate with those that indicate the presence of PTA. However, there are several signs/symptoms, namely, referred otalgia, cervical lymphadenopathy, and decreased oral intake, that were associated with PTA but unassociated with treatment. Treatment can be aided by establishing an algorithm that accounts for the symptoms/signs most correlated with true, drainable abscess.
4 citations
••
TL;DR: A comprehensive, telemedicine-enabled, stroke care delivery system that combines “drip and ship” and “ drip and keep” models with a comprehensive stroke center primary hub at Ochsner Medical Center in New Orleans, advanced stroke-capable regional hubs, and geographically-aligned, “stroke-ready” spokes is described.
Abstract: United States (US) and worldwide telestroke programs frequently focus only on emergency room hyper-acute stroke management. This article describes a comprehensive, telemedicine-enabled, stroke care delivery system that combines "drip and ship" and "drip and keep" models with a comprehensive stroke center primary hub at Ochsner Medical Center in New Orleans, advanced stroke-capable regional hubs, and geographically-aligned, "stroke-ready" spokes. The primary hub provides vascular neurology expertise via telemedicine and monitors care for patients remaining at regional hubs and spokes using a multidisciplinary team approach. By 2014, primary hub telestroke consults grew to ≈1000/year with 16 min average door to consult initiation and 20 min to completion, and 29% of ischemic stroke patients received recombinant tissue-type plasminogen activator (rtPA), increasing 275%. Most patients remained in hospitals close to home, but neurointensive care and interventional procedures were common reasons for primary hub transfer. Given the time sensitivity and expert consultation needed for complex acute stroke care delivery paradigms, telestroke programs are effective for fulfilling unmet care needs. Combining drip and ship and drip and keep management allows more patients to stay "local," limiting primary hub transfer unless more advanced services are required. Post admission telestroke management at spokes increases personnel efficiency and can positively impact stroke outcomes.
4 citations
•
4 citations
•
TL;DR: The 1987 Comprehensive Blood Bank Survey consisted of four shipments of samples that presented graded challenges in ABO and D typing, crossmatching, and antibody detection and identification and un graded challenges for antigen typing and ungraded serum samples for educational purposes.
Abstract: The 1987 Comprehensive Blood Bank Survey consisted of four shipments of samples Each presented graded challenges in ABO and D typing, crossmatching, and antibody detection and identification and ungraded challenges for antigen typing and ungraded serum samples for educational purposes Practice patterns were elicited through supplemental questions, generally about issues raised by the survey samples Two of the surveys showed significant problems Set J-C included serum with anti-Lea, which was not detected by some participants Anti-Dia was one of two antibodies in the J-D graded sample, and this additional antibody was not detected by a significant number of participants Although minor problems were encountered in other challenges, in general performance was good
4 citations
Authors
Showing all 993 results
Name | H-index | Papers | Citations |
---|---|---|---|
Carl J. Lavie | 106 | 1135 | 49318 |
Michael R. Jaff | 82 | 442 | 28891 |
Michael F. O'Rourke | 81 | 451 | 35355 |
Mandeep R. Mehra | 80 | 644 | 31939 |
Richard V. Milani | 80 | 454 | 23410 |
Christopher J. White | 77 | 621 | 25767 |
Bruce A. Reitz | 74 | 333 | 18457 |
Robert C. Bourge | 69 | 273 | 24397 |
Sana M. Al-Khatib | 69 | 377 | 17370 |
Hector O. Ventura | 66 | 478 | 16379 |
Andrew Mason | 63 | 360 | 15198 |
Aaron S. Dumont | 60 | 386 | 13020 |
Philip J. Kadowitz | 55 | 379 | 11951 |
David W. Dunn | 54 | 195 | 8999 |
Lydia A. Bazzano | 51 | 267 | 13581 |